|
The
National Ophthalmic Research Institute (NORI) is a physician-owned
clinical research center specializing in conducting clinical trials
of procedures and treatments for diseases of the eye related to
the retina and vitreous.
Its
mission is to provide patients access to ophthalmic drugs and devices
in clinical development that may improve their vision and quality
of life. NORI accomplishes this mission with a commitment to ethical
patient selection and retention, and superior research conduct in
accordance with Good Clinical Practice Guidelines as established
by the U.S. Food and Drug Administration (FDA). |
NORI
places a high priority on its commitment to the advancement
of medical research. The team of five physician specialists
associated with NORI has a prestigious history of active participation
with leading academic research institutions such as Harvard
Medical School’s affiliated Schepens Eye Research Institute,
where they all serve on the clinical faculty.
For
nearly 30 years, the NORI senior physicians and research coordinators
have conducted clinical trials for macular degeneration, diabetic
retinopathy, new diagnostic, surgical and laser techniques,
rehabilitation of low-vision patients, and other eye diseases.
The
NORI team is led by Glenn
L. Wing, M.D., Medical Director, who has been involved
in clinical research for more than 25 years in addition to
his medical practice at Retina Consultants of Southwest Florida®.
He is the past president of the Schepens International Society,
has led international conferences, and is highly regarded
for his work in retinal medicine. |
| NORI
is located in the modern office of Retina
Consultants of Southwest Florida, in Fort Myers, Florida,
one of the fastest growing areas in the United States with
a population base of more than 800,000 people in the region.
Its proximity to both I-75 and the Southwest Florida International
Airport (both within five miles) makes it easily
accessible for both patients and investigators.
NORI
has a dedicated research office with a full time staff. The
facility’s’ state-of-the-art equipment includes
multiple Topcon imaging systems with digital and film capabilities,
electrophysiology, spectral dimension OCT, standard Zeiss
OCT version 4, Paschal Laser, Heidelberg Retinal Angiograph,
Microperimeter 1, ultrasonography including real-time B scan,
diagnostic A scan, axial length, PDT Laser, Argon and Krypton
Laser, and a YAG.
Site
Services
Included in the NORI research headquarters are a
CLIA-exempt laboratory with centrifuge, a -20o
freezer, secure patient record storage with limited access,
designated drug storage refrigerators, multi-study certified
four meter visual acuity lanes, multiple lens sets, patient
exam rooms, pretest/history rooms, high-speed internet for
electronic data capture, private monitoring rooms with high-speed
internet and phone access.
|
|
|
 |
Left
to right:
Bottom Row: Donald C. Fletcher, MD; Glenn L. Wing, MD; Ashish G.
Sharma, MD
Top Row: Tom Ghuman, MD; Joseph P. Walker, MD; Paul A. Raskauskas,
MD |
The
physicians of the National Ophthalmic Research Institute are all
Fellowship-trained, and are Fellows of the American College of
Surgeons, members of the American Society of Retina Specialists,
American Academy of Ophthalmology, Harvard Medical School's affiliated
The Schepens Eye Research Institute Faculty, and the American
Medical Association.
Glenn
L. Wing, M.D., F.A.C.S.,
Medical Director
Joseph P. Walker, M.D., F.A.C.S.
Paul A. Raskauskas, M.D., F.A.C.S.
Tom Ghuman, M.D., F.A.C.S.
Ashish G. Sharma, M.D., F.A.C.S.
Low
Vision Rehabilitation Center
Donald C. Fletcher, M.D., Director
|
 |
 |
| NORI’s
investigators are well known in Southwest Florida as the largest,
most experienced team of retina specialists in the region with
four offices within a 40-mile radius.
Since
Southwest Florida is a popular retirement area, there is a large
patient population with age-related eye disease, such as macular
degeneration. Patients are from all ethnic backgrounds and socio-economic
groups, providing the type of diversity sought by many drug and
equipment manufacturers. |
| Learn
about our ongoing studies and find out if you qualify. |
|
|
